Bavarian Nordic Reports Strong Q1 2025 Growth

Bavarian Nordic A/S ( (BVNRY) ) has released its Q1 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its investors.

Bavarian Nordic A/S is a global vaccine company specializing in innovative vaccines for travel health and public preparedness, with a strong presence in the mpox and smallpox vaccine markets. The company, listed on the Nasdaq Copenhagen exchange, operates research and development facilities in Germany and the USA, and manufacturing sites in Denmark and Switzerland.

In its interim financial results for the first quarter of 2025, Bavarian Nordic reported a significant 62% increase in revenue, reaching DKK 1,347 million. This growth was primarily driven by strong performances in both its Travel Health and Public Preparedness segments. The company also achieved its first U.S. sales of the chikungunya vaccine following its approval earlier in the year.

Key financial highlights include a 52% increase in Travel Health revenue to DKK 680 million, and an 83% rise in Public Preparedness revenue to DKK 629 million. The operating profit (EBITDA) was DKK 420 million, with an EBITDA margin of 31%. The company maintained its financial guidance for the full year, expecting revenue between DKK 5,700-6,700 million and an EBITDA margin of 26-30%.

Strategically, Bavarian Nordic has made significant progress with its chikungunya vaccine, Vimkunya, which has been approved in the US and EU. The company is also expanding its regulatory approvals and has entered a partnership to improve vaccine access in low- and middle-income countries. Additionally, the freeze-dried version of the JYNNEOS vaccine was approved by the FDA, supporting ongoing contracts with the US government.

Looking ahead, Bavarian Nordic remains optimistic about its growth trajectory, with expectations of continued strong demand for its vaccines. The company is well-positioned to achieve its strategic goals, supported by a robust order book and ongoing efforts to expand its market reach.